RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. The company is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
RVL Pharmaceuticals Price Performance
RVL Pharmaceuticals stock traded up $0.01 during midday trading on Tuesday, reaching $1.60. 67,710 shares of the company were exchanged, compared to its average volume of 149,771. The company has a market capitalization of $133.68 million, a price-to-earnings ratio of -1.82 and a beta of 1.64. The firm's 50-day simple moving average is $1.38 and its 200-day simple moving average is $1.48. RVL Pharmaceuticals has a 1 year low of $0.98 and a 1 year high of $4.38. The company has a debt-to-equity ratio of 0.65, a quick ratio of 2.75 and a current ratio of 2.79.
RVL Pharmaceuticals (NASDAQ:RVLP - Get Rating) last posted its quarterly earnings data on Thursday, May 12th. The company reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.12. The firm had revenue of $21.44 million during the quarter, compared to analysts' expectations of $7.20 million. RVL Pharmaceuticals had a negative return on equity of 100.83% and a negative net margin of 163.45%. On average, analysts anticipate that RVL Pharmaceuticals will post -0.68 EPS for the current year.